You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Patent: 10,143,723


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,143,723
Title:Methods of using OX40 ligand encoding polynucleotides
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide. Also provided is a method for activating T cells or increasing the number of NK cells in a subject in need thereof.
Inventor(s): Frederick; Joshua P. (Boston, MA), Bai; Ailin (Newton, MA)
Assignee: ModernaTX, Inc. (Cambridge, MA)
Application Number:15/996,140
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,143,723
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the Patent Landscape: A Comprehensive Analysis of US Patent 10,143,723 and Related Issues

Introduction

Patent law in the United States is a complex and evolving field, particularly when it comes to the eligibility of patents under Section 101 of the Patent Act. This article will delve into the specifics of US Patent 10,143,723, and more broadly, the patent landscape, especially in the context of recent legal precedents and trends.

US Patent 10,143,723: An Overview

US Patent 10,143,723, titled "Methods of using OX40 ligand encoding polynucleotides," involves compositions and methods for the preparation, manufacture, and therapeutic use of polynucleotide molecules. This patent falls under the biotechnology sector, an area where patent eligibility can be particularly nuanced.

Section 101 Patent Eligibility: The American Axle Case

The American Axle case is a pivotal reference point for understanding Section 101 patent eligibility, especially for claims involving natural laws, physics, and mathematics. In this case, the Federal Circuit ruled that independent claim 22 of the ’911 patent was patent ineligible because it simply applied Hooke’s law to tune a propshaft liner without specifying the particular liners or the improved method of tuning[1].

Key Takeaways from American Axle

  • Specificity in Claims: The Federal Circuit emphasized the need for claims to have the specificity required to transform them from claiming only a result to claiming a way of achieving it. Claims must be "tethered to tangible equipment" and have "real-world impact"[1].
  • Natural Laws and Abstract Ideas: The court clarified that claims directed to natural laws or abstract ideas without additional limitations that provide a practical way of applying these concepts are ineligible under Section 101[1].
  • Dissenting Opinion: Judge Kimberly Moore's dissent highlighted the potential for confusion and the overreach of the majority's decision, arguing that the claims should be considered patent-eligible as they provided a specific solution to a problem[1].

Patent Quality and Section 101

The quality of patents is a critical issue, with low-quality patents leading to increased litigation and societal costs. The USPTO faces challenges in evaluating inventions against the standards of patentability due to information problems and shifting legal tests[3].

Incentives for Low-Quality Patents

  • Administrative Inefficiencies: Incentives for administrative agencies to conduct relatively ineffective examinations contribute to the issuance of low-quality patents[3].
  • High-Volume, Low-Quality Strategy: Modern innovative firms often adopt a strategy of filing a large number of patents, regardless of their individual worth, which can lead to a proliferation of low-quality patents[3].

Blockchain Patents: A Case Study

The landscape for blockchain patents provides an interesting contrast and insight into how different technologies are treated under Section 101.

Trends in Blockchain Patents

  • Filing and Issuance: Between 2013 and 2023, nearly 14,000 blockchain-based patent applications were filed, with almost 10,000 patents issued. This indicates a significant interest and success in patenting blockchain technology[4].
  • Top Patent Holders: Advanced New Technologies, IBM, and Bank of America are among the top holders of blockchain patents, reflecting the active involvement of both tech and financial institutions in this space[4].

Alice-Mayo Test and Blockchain

The Alice-Mayo test, as outlined in the USPTO's 2019 Revised Patent Subject Matter Eligibility Guidance, is crucial for determining the patentability of blockchain claims. Well-drafted blockchain patent applications can pass muster, but they must avoid being too abstract or result-oriented[4].

Practical Tips for Drafting Patent Applications

Given the complexities and challenges in the patent landscape, here are some practical tips for drafting patent applications that are likely to survive Section 101 challenges:

Specificity and Tangibility

  • Ensure that claims are specific and tethered to tangible equipment or processes, avoiding abstract ideas and natural laws without additional practical limitations[1].

Real-World Impact

  • Claims should have real-world impact and provide a concrete solution to a problem, rather than just claiming a result[1].

Detailed Claim Limitations

  • Include detailed claim limitations and dependent claims that reflect the physical structure or steps involved in the invention. This helps in distinguishing the claims from abstract ideas or natural laws[1].

Blend Specification into Claims

  • Assess the strengths and weaknesses of claim limitations and blend more detail from the specification into the claims to avoid result-oriented drafting[1].

The Role of Patent Claims Research Dataset

The Patent Claims Research Dataset provided by the USPTO offers valuable insights into patent claims and their structures. This dataset can help in understanding trends and best practices in drafting patent claims, including those related to specificity, dependency, and scope[2].

Conclusion

The patent landscape in the United States is dynamic and influenced by various legal and technological factors. The American Axle case sets important guideposts for patent eligibility under Section 101, emphasizing the need for specificity and real-world impact in claims. The trends in blockchain patents highlight the potential for successful patenting in emerging technologies when applications are well-drafted. By understanding these nuances and applying practical tips, patent applicants can better position their inventions for approval and protection.

Key Takeaways

  • Specificity in Claims: Ensure claims are specific and tethered to tangible equipment or processes.
  • Real-World Impact: Claims should have real-world impact and provide a concrete solution.
  • Detailed Claim Limitations: Include detailed claim limitations and dependent claims.
  • Blend Specification into Claims: Assess and blend more detail from the specification into the claims.
  • Patent Quality: Low-quality patents can lead to increased litigation and societal costs.

FAQs

What is the significance of the American Axle case in patent law?

The American Axle case is significant because it sets guideposts for patent eligibility under Section 101, emphasizing the need for specificity and real-world impact in claims to avoid being deemed abstract or directed to natural laws.

How many blockchain-based patent applications have been filed and issued in the US?

Between 2013 and 2023, nearly 14,000 blockchain-based patent applications were filed, with almost 10,000 patents issued.

What are the key incentives leading to low-quality patents?

Incentives include administrative inefficiencies, high-volume, low-quality patenting strategies by firms, and information problems in evaluating inventions against patentability standards.

What is the Alice-Mayo test, and how does it apply to blockchain patents?

The Alice-Mayo test is a framework for determining patent eligibility, particularly relevant for blockchain claims. It requires that claims not be too abstract or result-oriented and must include practical limitations to be eligible.

How can patent applicants ensure their claims are specific and tangible?

Applicants should ensure claims are tethered to tangible equipment or processes, include detailed claim limitations, and blend specification details into the claims to avoid abstract or result-oriented drafting.

Sources

  1. Crowell & Moring LLP, "The Conclusion of Am. Axle: Considerations Relating to Section 101 Patent Eligibility in the Context of Artificial Intelligence and Machine Learning," August 21, 2023.
  2. USPTO, "Patent Claims Research Dataset," August 28, 2017.
  3. University of Pennsylvania Law Review, "Understanding Patent-Quality Mechanisms," Vol. 157: 2135.
  4. Mintz, "Is Your Blockchain Invention Patentable?" May 29, 2024.

More… ↓

⤷  Subscribe

Details for Patent 10,143,723

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bristol-myers Squibb Company YERVOY ipilimumab Injection 125377 March 25, 2011 ⤷  Subscribe 2035-12-23
Merck Sharp & Dohme Llc KEYTRUDA pembrolizumab For Injection 125514 September 04, 2014 ⤷  Subscribe 2035-12-23
Merck Sharp & Dohme Llc KEYTRUDA pembrolizumab Injection 125514 January 15, 2015 ⤷  Subscribe 2035-12-23
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 December 22, 2014 ⤷  Subscribe 2035-12-23
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 October 04, 2017 ⤷  Subscribe 2035-12-23
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 August 27, 2021 ⤷  Subscribe 2035-12-23
Genentech, Inc. TECENTRIQ atezolizumab Injection 761034 May 18, 2016 ⤷  Subscribe 2035-12-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.